700 Technology Square
4 articles with Tiburio Therapeutics
Tiburio Announces Publication of Preclinical TBR-760 Data in Non-Functioning Pituitary Adenoma in Journal of the Endocrine Society
CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Tiburio Therapeutics Inc., a clinical stage company developing therapies for rare endocrine diseases, today published new data from a preclinical study in the Journal of the Endocrine Society demonstrating that its lead clinical asset, TBR-760, a dopamine somatostatin chimeric compound, arrests aggressive non-functioning pituitary adenoma (NFPA) growth in a mouse model. The pre-clinical data indicate that TBR-760 completely arrested tumor gr
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
Tiburio Therapeutics Inc. (Tiburio), a private biopharmaceutical company focused on developing treatments for rare neuroendocrine tumors and endocrine diseases, today announced the appointment of Nerissa Kreher, MD, to the newly created position of Chief Medical Officer.
Cydan Announces Formation of Tiburio Therapeutics Inc. to Develop Treatments for Rare Neuroendocrine Tumors and Endocrine Diseases
Tiburio raises $31M in a Series A round to advance two clinical stage compounds TBR-760, for the treatment of nonfunctioning pituitary adenoma (NFPA), and TBR-065 for rare endocrine diseases